NCT06594445View on ClinicalTrials.gov

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 19, 2024

Primary Completion Date

March 30, 2027

Study Completion Date

October 30, 2027

Conditions
Myeloid MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

GTB-360

"GTB-3650 is administered by a continuous infusion (CI). A patient's dose of GTB-3650 is calculated using their assigned Dose Level and their actual body weight (ABW) obtained within 5 days prior to or on Cycle 1, Day 1.~Dose Level 1: 1.25 ug/kg/day Dose Level 2: 2.5 ug/kg/day Dose Level 3: 5 ug/kg/day Dose Level 4: 10 ug/kg/day Dose Level 5: 25 ug/kg/day Dose Level 6: 50 ug/kg/day Dose Level 7: 100 ug/kg/day"

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER